Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

Area of Science:

• Hepatology
• Oncology
• Immunotherapy

Background:

• Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer.
• Surgical resection, while curative for early stages, is associated with high recurrence rates.
• Novel therapeutic strategies are needed to improve outcomes for HCC patients.

Purpose of the Study:

• To evaluate the role of immune checkpoint inhibitors (ICIs) as a neoadjuvant treatment for HCC.
• To assess the impact of neoadjuvant ICIs on recurrence rates and mortality post-surgery.
• To review the efficacy and safety of ICI monotherapy in clinical trials for HCC.

Main Methods:

• Review of clinical trial data on neoadjuvant immune checkpoint inhibitor therapy for HCC.
• Analysis of recurrence rates and survival outcomes in patients treated with neoadjuvant ICIs.
• Assessment of response rates (complete/partial) to neoadjuvant ICI treatment.

Main Results:

• Neoadjuvant ICI treatment demonstrates potential in reducing HCC recurrence after surgical resection.
• ICI monotherapy has shown efficacy in achieving complete or partial responses in HCC patients.
• Clinical trials support the safety and effectiveness of ICIs in the neoadjuvant setting for liver cancer.

Conclusions:

• Immune checkpoint inhibitors represent a promising neoadjuvant strategy for HCC, improving surgical outcomes.
• ICI monotherapy is a viable option for neoadjuvant treatment, offering significant benefits for HCC patients.
• Further research and clinical application of neoadjuvant ICIs are warranted for liver cancer management.